J-Gaba CR Sustained Release Tablet 300 mg (Pregabalin)

Adult dosage

This medication is taken once daily after the evening meal. It should be swallowed whole, and not divided, crushed, or chewed. The starting dosage can be 150 mg once daily. Based on individual patient response and tolerance, the dosage can be increased to a maximum of 600 mg once daily at weekly intervals. When discontinuing the medication, it should be gradually reduced with a gap of at least one week.

This medication may increase the risk of suicidal thoughts or behavior; therefore, if depression or mood changes occur during treatment, notify your doctor immediately. Do not use this medication if you are allergic to pregabalin or any of its ingredients. In diabetic patients, if weight gain occurs after this medication, it may be necessary to adjust the dosage of blood sugar control medications. If symptoms of angioedema appear, such as swelling of the face, mouth, or throat, stop taking the medication immediately and consult a doctor. Elderly patients may experience symptoms such as dizziness, drowsiness, or confusion, so caution should be exercised when starting treatment. This medication may cause blurred vision or other changes in vision; if these symptoms occur, consult a physician. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, anxiety, and nausea, so it should be gradually reduced under medical advice. If there is a history of substance abuse or mental illness, watch carefully for the risk of abuse when using this medication. Patients with impaired kidney function may need dosage adjustment. It should be administered with caution in patients with severe heart disease, as symptoms of heart failure may develop. Caution should be taken as co-administration with opioid analgesics increases the risk of central nervous system depression. Patients with compromised respiratory function or the elderly may be at higher risk for severe respiratory depression, necessitating dosage adjustments. During early pregnancy, there may be a risk of fetal malformation, so unless there is a specific reason, it should not be used during pregnancy, and women of childbearing age should use effective contraceptive methods. Breastfeeding females should consider discontinuing breastfeeding or the medication, as this drug may be passed into breast milk and affect the infant. Activities requiring attention, such as driving or operating machinery, should be avoided until drowsiness or dizziness resolves after taking this medication. In case of overdose, symptoms such as confusion, drowsiness, seizures may occur, and treatments like hemodialysis may be necessary if required. This medication should be kept out of the reach of children and should not be transferred to other containers. If symptoms such as skin rash, severe allergic reactions, or difficulty breathing occur while taking this medication, discontinue use and consult medical personnel immediately.

Serious side effects

Hives, angioedema, facial swelling, swelling of the face, mouth and upper airway, severe respiratory depression associated with respiratory or neurological disorders, breathing difficulties, pulmonary edema, cold sweat, facial flushing, severe edema, generalized edema, deep vein thrombosis, hypotension, tachycardia, sinus bradycardia, sinus arrhythmia, atrial fibrillation, deep vein thrombosis, severe allergic reactions, serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), sudden

Mild side effects

• Dizziness
• drowsiness
• headache
• confusion
• sedation
• constipation
• indigestion
• nausea
• dry mouth
• vomiting

Store this medication tightly closed to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to preserve the effectiveness of the medication.

Appearance

White to pale yellow, rectangular, film-coated extended-release tablet

Package unit

30 tablets (6 tablets/PTP x 5)